Patent: 10,478,497
✉ Email this page to a colleague
Summary for Patent: 10,478,497
Title: | Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer |
Abstract: | The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol. |
Inventor(s): | Benjamin; Susan (Chatillon, FR), Planquette; Cecile (Palaiseau, FR), Delansorne; Remi (Paris, FR) |
Assignee: | HYBRIGENICS S.A. (Paris, FR) |
Application Number: | 15/655,394 |
Patent Claims: | see list of patent claims |
Details for Patent 10,478,497
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | 11/16/2015 | ⤷ Try a Trial | 2039-12-05 |
Sanofi-aventis U.s. Llc | SARCLISA | isatuximab-irfc | Injection | 761113 | 03/02/2020 | ⤷ Try a Trial | 2039-12-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |